John Libbey Eurotext

European Journal of Dermatology

MENU

Efficacy of taxane regimens in patients with metastatic angiosarcoma Volume 21, numéro 4, July-August 2011

Auteurs
Departments of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Management Science, Graduate School of Engineering, Tokyo University, Japan, Clinical Laboratory, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Department of Surgical Pathology, Sapporo School of Medicine, Sapporo, Japan, Orthopedic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan, Dermatology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

The purpose of this study was to evaluate the efficacy of taxane regimens in patients with metastatic angiosarcoma. Forty-one patients with metastatic angiosarcoma treated at the National Cancer Center Hospital between January 1982 and January 2009 were retrospectively classified into 3 groups according to the treatment type: (i) taxane ( n=11), (ii) non-taxane ( n=14), and (iii) best supportive care (BSC; n=16) groups. The taxane group received paclitaxel ( n=6), docetaxel ( n=4), or albumin-bound paclitaxel ( n=1), and the non-taxane group received mainly doxorubicin-containing regimens ( n=12). The differences in progression-free survival (PFS) among the 3 groups were statistically significant ( P<0.001). After adjusting for prognostic factors, the taxane group had significantly longer PFS than the non-taxane (hazard ratio=0.282; 95% confidence interval=0.086-0.923; P=0.036) and BSC (hazard ratio=0.015; 95% confidence interval = 0.003-0.083; P<0.001) groups. Overall survival was also significantly longer in the taxane group than in the other groups. A taxane regimen may be more effective than a non-taxane regimen for treating patients with metastatic angiosarcoma.